FID-031 / Fulgent Genetics - LARVOL DELTA

Novel HER2 antibody drug conjugates with stable hydrophilic linkers (AACR 2026) - "Background: The success of Trastuzumab deruxtecan (T-DXd) was previously attributed to its unique cleavable linker and membrane permeable payload. FID-031 is a novel HER2-targeting ADC with improved PK profile, tissue distribution, and efficacy. This study provides fresh insights on the design considerations for ADC development aimed towards improving safety and overcoming drug resistance."

ADC • Oncology • HER-2